Dextromethorphan Interactions

Contraindicated due to risk of psychosis or bizarre behavior with MAO inhibitors including selective MAO-B inhibitors.

Source: NLP:rasagiline

Combination with MAO inhibitors has been reported to cause brief episodes of psychosis or bizarre behavior. Dextromethorphan is contraindicated due to rasagiline's MAO inhibitory activity.

Source: NLP:rasagiline mesylate

Combination with MAOIs has been reported to cause episodes of psychosis or bizarre behavior.

Source: NLP:safinamide mesylate

Abiraterone increased dextromethorphan Cmax and AUC 2.8- and 2.9-fold respectively. Avoid concomitant use or consider dose reduction.

Source: NLP:abiraterone

CYP2D6 substrate with 2.8-fold increase in Cmax and 2.9-fold increase in AUC when co-administered. Avoid co-administration or consider dose reduction.

Source: NLP:abiraterone acetate

Concomitant use may result in serotonin syndrome with serious CNS reactions, potentially fatal.

Source: NLP:methylene blue

Desvenlafaxine increases dextromethorphan levels. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment needed with 100 mg or lower.

Source: NLP:desvenlafaxine

Desvenlafaxine increases dextromethorphan exposure. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment needed with 100 mg or lower.

Source: NLP:desvenlafaxine er

Concomitant use increases exposure (Cmax and AUC). Reduce dose by up to one-half if co-administered with 400 mg desvenlafaxine.

Source: NLP:desvenlafaxine succinate

Increased risk of serotonin syndrome when combined with lasmiditan; use with caution.

Source: NLP:lasmiditan

Combined use of memantine with dextromethorphan has not been systematically evaluated and should be approached with caution due to both being NMDA antagonists.

Source: NLP:memantine

Combined use with memantine has not been systematically evaluated. Both are NMDA antagonists and such use should be approached with caution.

Source: NLP:memantine hydrochloride oral

Combined use of memantine with dextromethorphan (NMDA antagonist) has not been systematically evaluated and should be approached with caution.

Source: NLP:memantine hydrochloride and donepezil hydrochloride

Paroxetine inhibits CYP2D6, increasing dextromethorphan exposure. Decrease dextromethorphan dosage if needed with concomitant paroxetine use.

Source: NLP:paroxetine

Paroxetine inhibits CYP2D6, increasing exposure of dextromethorphan. Dosage reduction may be needed.

Source: NLP:paroxetine hydrochloride

2.3-fold increase in plasma concentrations with inhibitory effect persisting beyond 28 days.

Source: NLP:rolapitant

Terbinafine increases dextromethorphan/dextrorphan metabolite ratio by 16- to 97-fold, converting extensive CYP2D6 metabolizers to poor metabolizer status.

Source: NLP:terbinafine

Terbinafine increases dextromethorphan/dextrorphan metabolite ratio by 16- to 97-fold, converting extensive metabolizers to poor metabolizer status. Careful monitoring and dose reduction may be required.

Source: NLP:terbinafine hydrochloride

Terbinafine increases dextromethorphan/dextrorphan metabolite ratio by 16- to 97-fold, potentially converting extensive metabolizers to poor metabolizer status.

Source: NLP:terbinafine tablets 250 mg